EU and US could reach trade deal this weekend - Reuters
Frank M. Svoboda, Co-Chairman and CEO of Globe Life Inc. (NYSE:GL), recently executed a series of stock transactions. On June 4, 2025, Svoboda sold a total of 6,051 shares of the company’s common stock. The shares were sold at prices ranging from $121.1932 to $121.747 per share, resulting in total proceeds of approximately $733,616. The transaction occurred as Globe Life, currently valued at $10 billion, trades near InvestingPro’s Fair Value estimate, with a "GREAT" overall financial health score and an attractive P/E ratio of 9.8.
In addition to the sales, Svoboda acquired 7,500 shares through the exercise of employee stock options at a price of $82.56 per share, totaling $619,200. Following these transactions, Svoboda holds 32,747 shares directly. Furthermore, he maintains indirect ownership of 144,898 shares through a family trust and 1,939.642 shares via a 401(k) plan. InvestingPro analysis reveals management has been actively buying back shares, one of several key insights available in the comprehensive Pro Research Report covering Globe Life among 1,400+ top US stocks.
In other recent news, Globe Life reported its first-quarter earnings for 2025, showing a miss on earnings per share (EPS) estimates. The company posted an EPS of $3.07, which was below the forecasted $3.24, although revenue exceeded expectations, reaching $1.48 billion against a forecast of $1.45 billion. Despite the earnings miss, life insurance premium revenue grew by 3% to $830 million, and health insurance premium revenue increased by 8% to $370 million. Evercore ISI adjusted its price target on Globe Life shares, reducing it from $143.00 to $141.00 while maintaining an Outperform rating, following weaker-than-expected performance in the health insurance sector. Health insurance earnings decreased by approximately 8% from the previous quarter due to higher claims in Medicare supplement insurance. However, Globe Life’s overall earnings guidance for the year remains unchanged, thanks to a significant life insurance reserve release. The company anticipates health earnings will recover, with margins expected to improve in 2026 and 2027. Additionally, Globe Life is expected to announce its plans for utilizing its Bermuda captive reinsurance vehicle along with its second-quarter results, which could potentially accelerate share repurchases in the coming years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.